Compare Akamai Technologies, Inc. (AKAM) vs Colgate-Palmolive Company (CL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Akamai Technologies, Inc. vs Colgate-Palmolive Company — how do they compare? Akamai Technologies, Inc. trades at $123.2 (market cap $16.77B), while Colgate-Palmolive Company trades at $92.78 (market cap $73.59B). The key difference: Colgate-Palmolive Company is far larger — about 4.4× Akamai Technologies, Inc.'s market cap, and Colgate-Palmolive Company pays a 2.3% dividend while Akamai Technologies, Inc. pays none. Which is the better fit depends on your goals.
| AKAM | CL | |
|---|---|---|
Market Cap | $16.77B | $73.59B |
Sector | Technology | Consumer Staples |
52-Week High | $161.14 | $99.14 |
52-Week Low | $71.97 | $74.98 |
Enterprise Value | $22.75B | $80.07B |
Dividend Yield | — | 2.3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Akamai Technologies (AKAM) trades at $123.20, up 4.72% with strong quarterly earnings beats and accelerating cloud infrastructure growth. The stock shows mixed technical signals with bearish moving averages but neutral oscillators. Recent Q2 2026 results exceeded expectations with $1.59 EPS versus $1.57 estimate, driven by 39% growth in Cloud Infrastructure Services. However, net income margins have declined from 14.47% in 2022 to 9.51% currently due to increased infrastructure investments.
Akamai presents a compelling growth story in AI and cybersecurity markets with analyst consensus target of $150.11 suggesting 22% upside potential. Key risks include margin pressure from heavy infrastructure spending and competitive threats in cloud services. The balanced analyst rating distribution (47% Buy, 49% Hold) reflects cautious optimism about the company's strategic positioning amid ongoing profitability challenges.
Colgate-Palmolive (CL) trades at $92.66, down 0.53% on the day, with a neutral technical signal. The company reported Q2 2026 EPS of $0.99, beating estimates, with 4.9% sales growth driven by strength in Latin America and Asia Pacific, though North American performance remains weak. Operating cash flow remains robust at $4.20 billion for 2025. The stock is trading below the consensus price target of $99.10.
The outlook is mixed, with strong profitability and consistent earnings beats offset by high valuation multiples and domestic market challenges. The primary opportunity lies in international growth and margin expansion, while risks include intense competition and reliance on emerging markets for growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Akamai Technologies, Inc.
Akamai operates a content delivery network, or CDN, which entails locating servers at the edges of networks so its customers, which store content on Akamai servers, can reach their own customers faster, more securely, and with better quality. Akamai has over 325,000 servers distributed over 4,000 points of presence in more than 1,000 cities worldwide. Its customers generally include media companies, which stream video content or make video games available for download, and other enterprises that run interactive or high-traffic websites, such as e-commerce firms and financial institutions. Akamai also has a significant security business, which is integrated with its core web and media businesses to protect its customers from cyberthreats.
Read more on AKAM →About Colgate-Palmolive Company
Since its founding in 1806, Colgate-Palmolive has grown to become a leading global consumer product company. In addition to its namesake oral care line, the firm manufactures shampoos, shower gels, deodorants, and home care products that are sold in over 200 countries (international sales account for about 70% of its consolidated total, including approximately 45% from emerging regions). It also owns specialty pet food maker Hill's, which sells its products through veterinarians and specialty pet retailers.
Read more on CL →
